UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Cancer discovery, 2020-08, Vol.10 (8), p.1194-1209

2020

Volltextzugriff (PDF)

Circulating MicroRNA Is a Biomarker of Pediatric Crohn Disease

Journal of pediatric gastroenterology and nutrition, 2011-07, Vol.53 (1), p.26-33

2011

Volltextzugriff (PDF)

Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation

The Journal of pediatrics, 2012-01, Vol.160 (1), p.122-128

2012

Volltextzugriff (PDF)

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

The Journal of pediatrics, 2008-10, Vol.153 (4), p.484-490.e2

2008

Volltextzugriff (PDF)

Increases in Sex Hormones during Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease

The Journal of pediatrics, 2016-04, Vol.171, p.146-152.e2

2016

Volltextzugriff (PDF)

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study

Cancer treatment and research communications, 2024, Vol.40, p.100832, Article 100832

2024

Volltextzugriff (PDF)

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO clinical and research reports, 2021-02, Vol.2 (2), p.100104, Article 100104

2021

Volltextzugriff (PDF)

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2017-06, Vol.152 (8), p.1901-1914.e3

2017

Volltextzugriff (PDF)

Skeletal Health of Children and Adolescents With Inflammatory Bowel Disease

Journal of pediatric gastroenterology and nutrition, 2011-07, Vol.53 (1), p.11-25

2011

Volltextzugriff (PDF)

A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS279-TPS279

2023

Volltextzugriff (PDF)

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.468-477

2024

Volltextzugriff (PDF)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Nature medicine, 2023-10, Vol.29 (10), p.2577-2585

2023

Volltextzugriff (PDF)

Amivantamab and lazertinib in treatment-naïve EGFR- mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9134-9134

2023

Volltextzugriff (PDF)

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.135-135

2024

Volltextzugriff (PDF)

Effects of Sex, Race, and Puberty on Cortical Bone and the Functional Muscle Bone Unit in Children, Adolescents, and Young Adults

The journal of clinical endocrinology and metabolism, 2010-04, Vol.95 (4), p.1681-1689

2010

Volltextzugriff (PDF)

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9132-TPS9132

2021

Volltextzugriff (PDF)

Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease

Inflammatory bowel diseases, 2016-06, Vol.22 (6), p.1370-1377

2016

Volltextzugriff (PDF)

Improvements in Bone Density and Structure during Anti-TNF-α Therapy in Pediatric Crohn's Disease

The journal of clinical endocrinology and metabolism, 2015-07, Vol.100 (7), p.2630-2639

2015

Volltextzugriff (PDF)

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9008-9008

2022

Volltextzugriff (PDF)

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9006-9006

2022

Volltextzugriff (PDF)

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

Annals of oncology, 2022-07, Vol.33, p.S482

2022

Volltextzugriff (PDF)

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.166-171

2023

Volltextzugriff (PDF)

Increases in IGF-1 After Anti–TNF-α Therapy Are Associated With Bone and Muscle Accrual in Pediatric Crohn Disease

The journal of clinical endocrinology and metabolism, 2018-03, Vol.103 (3), p.936-945

2018

Volltextzugriff (PDF)

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9006-9006

2021

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(59)
Buchkapitel
(1)

Sprache

Englisch
(57)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(30)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Female
(23)
Child
(22)
Male
(22)
Adolescent
(20)
Child, Preschool
(13)
Adult
(12)
Pediatrics
(12)
Crohn Disease - Drug Therapy
(11)
Gastroenterology & Hepatology
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Young Adult
(8)
Body Composition
(7)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(6)
Antibodies, Monoclonal - Therapeutic Use
(5)
Crohn Disease - Physiopathology
(5)
Endocrinology & Metabolism
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Circulating MicroRNA Is a Biomarker of Pediatric Crohn Disease

Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease

Increases in Sex Hormones during Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

Skeletal Health of Children and Adolescents With Inflammatory Bowel Disease

A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Amivantamab and lazertinib in treatment-naïve EGFR- mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study

Effects of Sex, Race, and Puberty on Cortical Bone and the Functional Muscle Bone Unit in Children, Adolescents, and Young Adults

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC

Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease

Improvements in Bone Density and Structure during Anti-TNF-α Therapy in Pediatric Crohn's Disease

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Increases in IGF-1 After Anti–TNF-α Therapy Are Associated With Bone and Muscle Accrual in Pediatric Crohn Disease

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Suchergebnisse filtern